ArticleCureus2026
Autoimmune Limbic Encephalitis With Leucine-Rich Glioma-Inactivated 1 (LGI1) Antibodies Presenting as Rapidly Progressive Cognitive Decline and Psychiatric Symptoms: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune limbic encephalitis (LE) with leucine-rich glioma-inactivated 1 (LGI1) antibodies is rare but treatable, often presenting as rapidly progressive cognitive decline, behavioural changes, and hyponatraemia. These features can resemble psychiatric or neurodegenerative disorders, delaying diagnosis. We report a case of a 63-year-old man with confusion, memory loss, dream enactment, hallucinations, severe hyponatraemia, and specific higher cortical features, including apraxia, anomia, and executive dysfunction. Faciobrachial dystonic seizures (FBDS), a recognised hallmark of LGI1 antibody-mediated LE, were not clearly appreciated at initial presentation in this case. MRI revealed bilateral medial temporal lobe abnormalities, while CSF and EEG results were unremarkable. LGI1 antibodies were identified only after initial neuronal antibody tests were negative. Treatment with corticosteroids and intravenous immunoglobulin (IVIg) stabilised his condition and led to partial improvement. This case underscores the diagnostic challenges of LGI1 antibody-associated LE and the importance of early recognition, antibody testing, and prompt immunotherapy to prevent irreversible neurological damage. The objective of this case report is to highlight the diagnostic pitfalls and management considerations in LGI1 antibody-mediated LE presenting predominantly with psychiatric and cognitive symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.